Pola-ZR2P in Previously Untreated DLBCL

This study is testing a new combination regimen called Pola-ZR2P — which includes polatuzumab vedotin (an antibody-drug conjugate that delivers chemotherapy directly into lymphoma cells), along with other drugs — as a first-line treatment for patients newly diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL), the most common aggressive type of blood cancer. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with Diffuse Large B-Cell Lymphoma confirmed by a biopsy - You have never received chemotherapy before for this condition - Your expected survival is at least 3 months - You are willing and able to follow all study visits and procedures **You may NOT be eligible if...** - You have an active serious infection requiring intravenous antibiotics within the past 14 days - You have severe heart, liver, kidney, or metabolic disease that is not well-controlled - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.